The Effect of Vırtual Realıty Glasses on Heart Faılure Patıents

Effects of Breathıng Exercıses wıth Vırtual Realıty Glasses on Anxıety Levels, Sleep Qualıty and Respıratory Parameters in Heart Faılure Patıents

Anxiety and sleep disorders are among the most common symptoms in heart failure patients. In addition to pharmacological methods for anxiety and sleep disorders, non-pharmacological methods can also be used. Among these, anxiety and sleep disorders can be prevented with virtual reality glasses aimed at distraction. This study will be conducted to evaluate the effect of breathing exercises performed with virtual reality glasses on anxiety, sleep quality, and respiratory parameters. The study will be conducted with a total of 45 patients, 15 virtual reality glasses + breathing exercises, 15 breathing exercises, and 15 controls. Those in the virtual reality glasses + breathing exercises group will perform breathing exercises with virtual reality glasses once a day for 7 days. Those in the breathing exercises group will perform only breathing exercises once a day for 7 days. Anxiety, sleep disorders, and respiratory parameters of the patients will be examined.

Study Overview

• Status: Not yet recruiting
• Conditions: Heart Failure
• Intervention / Treatment: Behavioral: Virtual reality glasses; Behavioral: breathing exercise

• Study Type: Interventional
• Enrollment (Estimated): 45
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Servet KALYONCUO; Phone Number: (458) 211-1176; Email: servetkalyoncu38@gmail.com
• Study Contact Backup: Name: Özlem CEYHAN; Email: ozlemg@erciyes.edu.tr

Study Locations

• Turkey
  • Talas
    • Kayseri, Talas, Turkey, 38000
      • T.C. Erciyes University Faculty of Medicine Hospitals
      • Contact: Servet Kalyoncuo; Phone Number: 05063096866; Email: servetkalyoncu38@gmail.com
      • Principal Investigator: Servet KALYONCUO

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• 18 years of age or older,
• Verbal communication,
• Place and time oriented,
• Without any psychiatric illness,
• Patients diagnosed with HF with NYHA class III-IV symptoms,
• Left ventricular ejection fraction ≥50% (LVEF-CF/HFpEF), between 40-49% (SEF-CF/HFmrEF), HF below 40% (DEF-CF/HFrEF),
• High levels of natriuretic peptides (BNP>35 pg/mL and/or NTproBNP>125 pg/mL),
• There is no deformity or diagnosis related to the musculoskeletal system that may prevent breathing exercise,
• Chronic diseases such as hypertension (Stage 1 and 2 HT) and diabetes mellitus are stable and the treatment for these diagnoses has not been changed in the last month,
• Who have not previously received respiratory exercise training and have not participated in a rehabilitation program,
• Patients who volunteer to participate in the study will be included in the study

Exclusion Criteria:

• Life signs are so abnormal as to preclude intervention,
• Patients with migraine, vertigo, active nausea-vomiting, headache, dizziness will not be included in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Virtual reality glasses + breathing exercise app	Behavioral: Virtual reality glasses; virtual reality glasses application; Behavioral: breathing exercise; breathing exercise app
Active Comparator: Breathing exercise practice	Behavioral: breathing exercise; breathing exercise app
No Intervention: Kontrol; No application will be made

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Anxiety level	Turkish adaptation of the state-trait anxiety inventory short version (STAIS-5, STAIT-5). This form is a 4-point Likert type. It is an easy-to-apply inventory consisting of a total of 10 statements. As the score obtained in this form increases, the level of anxiety also increases.	Apply the morning before application and the morning 7 days after application.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sleep Quality	Richard Campbell Sleep Quality Scale (RCSQ) for sleep quality level assessment.This form is a 6-item scale. According to the scale scoring, a score between "0-25" indicates very poor sleep, and a score between "76-100" indicates very good sleep.	Apply the morning before application and the morning 7 days after application.

Collaborators and Investigators

• Sponsor: Bayburt University
• Investigators: Principal Investigator: Servet Kalyoncuo, Erciyes University

Publications and helpful links

General Publications

• Polikandrioti M, Goudevenos J, Michalis LK, Koutelekos J, Kyristi H, Tzialas D, Elisaf M. Factors associated with depression and anxiety of hospitalized patients with heart failure. Hellenic J Cardiol. 2015 Jan-Feb;56(1):26-35.

Helpful Links

• referances

Study record dates

Study Major Dates

• Study Start (Estimated): October 1, 2025
• Primary Completion (Estimated): October 1, 2025
• Study Completion (Estimated): December 30, 2025

Study Registration Dates

• First Submitted: January 16, 2025
• First Submitted That Met QC Criteria: February 18, 2025
• First Posted (Actual): February 20, 2025

Study Record Updates

• Last Update Posted (Actual): July 3, 2025
• Last Update Submitted That Met QC Criteria: July 1, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Keywords: Anxiety; Heart failure; Sleep Quality; Respiration; Virtual reality glasses
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Heart Diseases; Heart Failure
• Other Study ID Numbers: RCS2253148

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No